These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31202634)

  • 1. ERT Degrades Gene Therapy for Storage Disorder.
    Markusic DM
    Mol Ther; 2019 Jul; 27(7):1207-1208. PubMed ID: 31202634
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease.
    Alliegro M; Ferla R; Nusco E; De Leonibus C; Settembre C; Auricchio A
    Mol Ther; 2016 Dec; 24(12):2054-2063. PubMed ID: 27658524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapies and future perspectives.
    Scarpa M; Frustaci A
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S109-10. PubMed ID: 20040320
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of lysosomal storage diseases: recent patents and future strategies.
    Ortolano S; Viéitez I; Navarro C; Spuch C
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategies for lysosomal storage disorders.
    Beck M
    Dev Med Child Neurol; 2018 Jan; 60(1):13-18. PubMed ID: 29090451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic approaches for lysosomal storage diseases: a patent update.
    Urbanelli L; Sagini K; Polidoro M; Brozzi A; Magini A; Emiliani C
    Recent Pat CNS Drug Discov; 2013 Aug; 8(2):91-109. PubMed ID: 23713988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolutionary redesign of the lysosomal enzyme arylsulfatase A increases efficacy of enzyme replacement therapy for metachromatic leukodystrophy.
    Simonis H; Yaghootfam C; Sylvester M; Gieselmann V; Matzner U
    Hum Mol Genet; 2019 Jun; 28(11):1810-1821. PubMed ID: 30657900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives from B cell immunology: fact and fancy.
    Hunt SV
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S86-99. PubMed ID: 20040318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging therapies for neuropathic lysosomal storage disorders.
    Kelly JM; Bradbury A; Martin DR; Byrne ME
    Prog Neurobiol; 2017 May; 152():166-180. PubMed ID: 27725193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.
    Macauley SL
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1(Suppl 1):639-48. PubMed ID: 27491211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New strategies for the treatment of lysosomal storage diseases (review).
    Parenti G; Pignata C; Vajro P; Salerno M
    Int J Mol Med; 2013 Jan; 31(1):11-20. PubMed ID: 23165354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases.
    Li M
    Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).
    Ries M
    J Inherit Metab Dis; 2017 May; 40(3):343-356. PubMed ID: 28314976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in treatment approaches of lysosomal storage diseases (LSDs).
    Rozenfeld PA
    Curr Pharm Biotechnol; 2011 Jun; 12(6):853. PubMed ID: 21506916
    [No Abstract]   [Full Text] [Related]  

  • 15. Current state of the management of LSDs.
    Germain DP; Aggio M
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S61-2. PubMed ID: 20040313
    [No Abstract]   [Full Text] [Related]  

  • 16. Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications.
    Biffi A
    Mol Ther; 2017 May; 25(5):1155-1162. PubMed ID: 28389320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: Genetics and Gene Therapy of Lysosomial Storage Disorders.
    Tuttolomondo A
    Curr Gene Ther; 2018; 18(2):66-67. PubMed ID: 29741137
    [No Abstract]   [Full Text] [Related]  

  • 18. [Lysosomal Storage Diseases: Challenges in Multiprofessional Patient Care with Enzyme Replacement Therapy].
    Das AM; Lagler F; Beck M; Scarpa M; Lampe C
    Klin Padiatr; 2017 May; 229(3):168-174. PubMed ID: 28464188
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease.
    Squeri G; Passerini L; Ferro F; Laudisa C; Tomasoni D; Deodato F; Donati MA; Gasperini S; Aiuti A; Bernardo ME; Gentner B; Naldini L; Annoni A; Biffi A; Gregori S
    Mol Ther; 2019 Jul; 27(7):1215-1227. PubMed ID: 31060789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.